Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Circ_nuclear factor I X (circNfix) attenuates pressure overload-induced cardiac hypertrophy via regulating miR-145-5p/ATF3 axis.

Tytuł:
Circ_nuclear factor I X (circNfix) attenuates pressure overload-induced cardiac hypertrophy via regulating miR-145-5p/ATF3 axis.
Autorzy:
Pan J; Department of Thoracic and Cardiovascular Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Xu Z; Department of Thoracic and Cardiovascular Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Guo G; Department of Thoracic and Cardiovascular Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Xu C; Department of Thoracic and Cardiovascular Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Song Z; Department of Thoracic and Cardiovascular Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Li K; Department of Thoracic and Cardiovascular Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Zhong K; Department of Thoracic and Cardiovascular Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Wang D; Department of Thoracic and Cardiovascular Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Źródło:
Bioengineered [Bioengineered] 2021 Dec; Vol. 12 (1), pp. 5373-5385.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin : Landes Bioscience
MeSH Terms:
Activating Transcription Factor 3*/genetics
Activating Transcription Factor 3*/metabolism
Cardiomegaly*/genetics
Cardiomegaly*/metabolism
Cardiomegaly*/pathology
MicroRNAs*/genetics
MicroRNAs*/metabolism
RNA, Circular*/genetics
RNA, Circular*/metabolism
Angiotensin II ; Animals ; Humans ; Mice ; Mice, Inbred C57BL ; Myocytes, Cardiac/cytology ; Signal Transduction
References:
Int J Mol Sci. 2018 Nov 03;19(11):. (PMID: 30400273)
PLoS One. 2013 Jul 03;8(7):e68396. (PMID: 23874609)
Acta Physiol (Oxf). 2019 Oct;227(2):e13323. (PMID: 31162869)
Annu Rev Physiol. 2003;65:45-79. (PMID: 12524460)
Circulation. 2017 May 23;135(21):2041-2057. (PMID: 28249877)
J Mol Cell Cardiol. 2016 Aug;97:245-62. (PMID: 27262674)
Stroke Vasc Neurol. 2019 Mar 2;4(2):96-98. (PMID: 31338219)
Nat Commun. 2019 Sep 20;10(1):4317. (PMID: 31541092)
In Vitro Cell Dev Biol Anim. 2020 Apr;56(4):286-295. (PMID: 32377998)
Cancer Lett. 2015 Sep 1;365(2):141-8. (PMID: 26052092)
J Neurosci. 2019 Sep 11;39(37):7369-7393. (PMID: 31311824)
Mol Cell Endocrinol. 2021 Apr 5;525:111140. (PMID: 33359304)
Clin Sci (Lond). 2019 Mar 1;133(5):611-627. (PMID: 30782608)
Gene. 2014 Feb 25;536(2):225-31. (PMID: 24378234)
RNA Biol. 2017 Aug 3;14(8):992-999. (PMID: 27617908)
J Cell Mol Med. 2019 Mar;23(3):1671-1677. (PMID: 30648807)
Neurochem Int. 2001 Jun;38(7):601-8. (PMID: 11290385)
RNA Biol. 2016;13(1):34-42. (PMID: 26669964)
J Cell Physiol. 2019 May;234(5):5588-5600. (PMID: 30341894)
J Cell Mol Med. 2018 Sep;22(9):4292-4303. (PMID: 29992755)
Bioengineered. 2021 Dec;12(1):1739-1751. (PMID: 34002668)
Nat Med. 2011 Nov 07;17(11):1391-401. (PMID: 22064429)
Liver Res. 2017 Sep;1(2):96-102. (PMID: 29242753)
Vascul Pharmacol. 2019 Mar;114:13-22. (PMID: 30910127)
Cancer Manag Res. 2020 Oct 02;12:9577-9587. (PMID: 33061643)
Aging (Albany NY). 2020 Feb 5;12(3):2530-2544. (PMID: 32023551)
Circulation. 2003 Mar 18;107(10):1424-32. (PMID: 12642365)
Cardiovasc Res. 2020 Jun 1;116(7):1323-1334. (PMID: 31397837)
J Cell Mol Med. 2019 Sep;23(9):5859-5867. (PMID: 31240820)
Basic Res Cardiol. 2012 Nov;107(6):307. (PMID: 23099820)
Biochim Biophys Acta Mol Basis Dis. 2020 Oct 1;1866(10):165848. (PMID: 32473999)
Circulation. 2019 Jun 18;139(25):2857-2876. (PMID: 30947518)
Genome Biol. 2015 Jun 16;16:126. (PMID: 26076956)
Int J Mol Sci. 2019 Sep 23;20(19):. (PMID: 31547607)
Pharmacol Ther. 2010 Oct;128(1):191-227. (PMID: 20438756)
Oncotarget. 2015 Aug 28;6(25):20773-84. (PMID: 26318584)
Nat Rev Cardiol. 2015 Mar;12(3):135-42. (PMID: 25511085)
Cardiovasc Res. 2011 May 1;90(2):234-42. (PMID: 21257612)
Circulation. 2006 Oct 10;114(15):1633-44. (PMID: 17030703)
Drug Des Devel Ther. 2020 Dec 29;14:5699-5710. (PMID: 33402817)
J Exp Clin Cancer Res. 2019 Dec 30;38(1):506. (PMID: 31888753)
Cell Death Dis. 2019 Aug 19;10(9):629. (PMID: 31427569)
Nat Rev Genet. 2019 Nov;20(11):675-691. (PMID: 31395983)
Bioengineered. 2021 Dec;12(1):1381-1390. (PMID: 33896365)
J Exp Clin Cancer Res. 2019 Sep 6;38(1):393. (PMID: 31492150)
Curr Mol Med. 2018;18(10):661-671. (PMID: 30714521)
Arch Biochem Biophys. 2020 Aug 15;689:108405. (PMID: 32439330)
Clin Epigenetics. 2016 Jan 15;8:4. (PMID: 26779291)
Toxicol Pathol. 2006;34(1):58-66. (PMID: 16507545)
J Biol Chem. 2018 Aug 24;293(34):13125-13133. (PMID: 29950523)
Eur Heart J. 2016 Sep 01;37(33):2602-11. (PMID: 26802132)
Neoplasma. 2019 Jun 29;66(6):879-886. (PMID: 31307199)
Biomed Pharmacother. 2018 Dec;108:1347-1356. (PMID: 30372837)
Eur J Pharmacol. 2020 Mar 15;871:172849. (PMID: 31843516)
EMBO J. 2019 Aug 15;38(16):e100836. (PMID: 31343080)
EBioMedicine. 2018 Oct;36:54-62. (PMID: 30297144)
Bioengineered. 2017 Jan 2;8(1):14-20. (PMID: 27791460)
Contributed Indexing:
Keywords: ATF3; Hypertrophy; Nfix; circNfix; circRNA; miRNA
Substance Nomenclature:
0 (ATF3 protein, human)
0 (Activating Transcription Factor 3)
0 (Atf3 protein, mouse)
0 (MIRN145 microRNA, human)
0 (MIRN145a microRNA, mouse)
0 (MicroRNAs)
0 (RNA, Circular)
11128-99-7 (Angiotensin II)
Entry Date(s):
Date Created: 20210901 Date Completed: 20211222 Latest Revision: 20231213
Update Code:
20240105
PubMed Central ID:
PMC8806771
DOI:
10.1080/21655979.2021.1960462
PMID:
34468254
Czasopismo naukowe
Cardiac hypertrophy can cause heart failure. However, the mechanisms underlying the progression of cardiac hypertrophy remain unclear. Emerging evidence suggests that circular RNAs (circRNAs) play a critical role in cardiac hypertrophy. However, the association between circ_nuclear factor I X (circNfix) and cardiac hypertrophy remain largely unknown. Therefore, the aim of the present study was to explore the role of circNfix in cardiac hypertrophy. In order to detect the function of circNfix in cardiac hypertrophy, cardiomyocytes were stimulated with angiotensin II (Ang II) to mimic the pathogenesis of the disease. In addition, pressure overload-induced cardiac hypertrophy in a mouse model was established using transverse aortic constriction (TAC) surgery. The mechanism via which circNfix regulated cardiac hypertrophy was investigated using RNA pull-down and luciferase reporter assays, and fluorescence in situ hybridization (FISH). circNfix was downregulated in Ang II-treated cardiomyocytes. Similarly, circNfix expression was markedly downregulated in mice following TAC surgery. In addition, circNfix overexpression significantly prevented the progression of cardiac hypertrophy in TAC-treated mice. Luciferase activity and RNA pull-down assays indicated that circNfix could indirectly target activating transcription factor 3 (ATF3) by binding with microRNA (miR)-145-5p in cardiomyocytes. miR-145-5p overexpression or ATF3 knockdown could reverse the effects of circNfix in Ang II-treated mouse cardiomyocytes. circNfix attenuated pressure overload-induced cardiac hypertrophy by regulating the miR-145-5p/ATF3 axis. Therefore, circNfix may serve as a molecular target for cardiac hypertrophy treatment.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies